Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Difelikefalin - Cara Therapeutics

Drug Profile

Difelikefalin - Cara Therapeutics

Alternative Names: CKD-943; CR-845; CR845/difelikefalin; Difelikefalin acetate - Cara Therapeutics; FE-202845; Kapruvia; KORSUVA; Korsuva; MR13A9

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Cara Therapeutics; Chong Kun Dang; CSL Vifor; Kissei Pharmaceutical; Maruishi Pharmaceutical; Vifor Fresenius Medical Care Renal Pharma
  • Class Amines; Analgesics; Antipruritics; Carboxylic acids; Opioid analgesics; Peptides; Piperidines; Skin disorder therapies; Urologics
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Pain; Postoperative pain

Highest Development Phases

  • Marketed Pruritus
  • Phase III Pain; Postoperative pain

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for clinical-Phase-Unknown development in Pain in USA (IV)
  • 28 Feb 2024 No recent reports of development identified for phase-I development in Pain in Japan (IV)
  • 22 Jan 2024 Cara Therapeutics terminates phase-III KICK 1 trial in Pruritus (Treatment-experienced in USA (PO), as company wants to discontinue the phase III programme (NCT05342623)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top